The ART1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population generated from HeLa cells, featuring targeted disruption of the ART1 gene. This polyclonal format provides a heterogeneous pool of edited cells, offering a robust loss-of-function model for investigating mono-ADP-ribosylation without the biases of single-cell cloning. The ablation of ART1-mediated arginine-specific ADP-ribosylation of cell surface proteins allows researchers to interrogate the functional consequences of this modification in a cancer cell background.
The HeLa cell line is an immortalized human cervical adenocarcinoma line with an aneuploid karyotype, isolated from a cervical tumor and extensively used in biomedical research. HeLa cells are highly permissive to numerous pathogens, including viruses and bacteria, making them a preferred model for studying host-pathogen interactions. Their epithelial origin and transformed phenotype also provide a relevant system for examining cell adhesion, migration, and inflammatory signaling in the context of cervical cancer.
ART1 encodes a cell surface mono-ADP-ribosyltransferase that catalyzes the transfer of ADP-ribose from NAD? to specific arginine residues on target proteins. Key substrates include integrin alpha7, CD8, and the P2X7 receptor, whose modification alters their activity and downstream signaling. This enzymatic activity is tightly regulated by upstream inflammatory stimuli: IFN-??, TNF-??, IL-1??, and lipopolysaccharide (LPS) activate ART1 expression and function. Downstream, ART1-mediated ADP-ribosylation modulates NF-??B signaling pathways, cell adhesion dynamics via integrin alpha7-fibronectin interactions, and actin cytoskeleton remodeling. Additionally, ART1 interacts with fibronectin and influences CD8-mediated immune recognition, positioning it at the nexus of inflammation and cell adhesion.
In the HeLa cervical adenocarcinoma environment, ART1-driven ADP-ribosylation likely contributes to malignant phenotypes such as enhanced cell adhesion, immune evasion, and the generation of a pro-inflammatory microenvironment. By eliminating ART1, this knockout model enables the dissection of how arginine mono-ADP-ribosylation impacts tumor cell behavior. For example, loss of integrin alpha7 ADP-ribosylation may reduce adhesion to fibronectin and impair migration, while abrogation of CD8 modification could alter immune cell interactions. The HeLa cells’ permissiveness to pathogens also facilitates investigations into ART1’s role in infection-triggered inflammatory cascades, linking innate immune signaling to cancer progression.
Researchers can utilize this polyclonal knockout population to explore the biological functions of ADP-ribosylation in diverse contexts, including cancer biology, immune regulation, and inflammatory disease. Typical experimental approaches include ADP-ribosylation assays to measure enzyme activity, cell adhesion and migration assays to assess functional outcomes, flow cytometry for surface protein expression analysis, and co-immunoprecipitation to map protein interactions. Transcriptional profiling by RT-qPCR and protein validation by Western blotting complement these studies. The model is well-suited for drug target validation and high-content screening for modulators of ART1 activity. For further information on experimental support and technical specifications, please contact Ascent Research.
